KalVista Pharmaceuticals (KALV) Receivables (2017 - 2025)

KalVista Pharmaceuticals (KALV) reported Receivables of $1.9 million for Q3 2025, up 2538.36% sequentially from $73000.0 in Q3 2017.

KalVista Pharmaceuticals (KALV) Receivables (2017 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 2 years of Receivables data on file, last reported at $1.9 million in Q3 2025.

For the quarter ending Q3 2025, Receivables changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Jul 2025 stood at $1.9 million (changed N/A YoY), and the FY2025 full-year result was $10.9 million, changed N/A from the prior year.
Receivables improved to $1.9 million in Q3 2025, from $73000.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $1.9 million in Q3 2025 to a low of $1.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn	1.93 Mn

Download Data